Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)

ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS. Related Content: Sevoflurane Sedation in Acute Respiratory Distress Syndrome Inhaled Sedation in Acute Respiratory Distress Syndrome

You can listen to Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS) online on Radio and Podcast. Open the player on this page to stream the available audio.

Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS) is an episode from JAMA Author Interviews: Covering research in medicine, science, & clinical practice. For physicians, researchers, & clinicians. by American Medical Association.

This episode is 18:08 long.

This episode was published on Mar 18, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from JAMA Author Interviews: Covering research in medicine, science, & clinical practice. For physicians, researchers, & clinicians. when more episodes are available from the podcast feed.